To test such hypothesis, we applied immunocompetent preclinical models of glioblastoma (using GL261 and GL261‐luc cells) and designed single and combination therapies with AMG386 (Trebananib, a first‐in‐class Ang‐1/2 neutralizing peptibody) and aflibercept (Zaltrap®, also known as VEGF‐trap that blocks VEGF‐A, VEGF‐B, and placenta growth factor (PlGF; see Materials and Methods) (Holash et al, 2002; Coxon et al, 2010). Here, VEGFA is linked to glioblastoma.